*Click here for the transcript of this video interview: aging-us.net/2022/06/15/inter...
Dr. Mikhail Blagosklonny is a professor of oncology who now studies aging, and is the originator of the hyperfunction theory of aging. He has written numerous scientific articles on aging and, in particular, on the extension of lifespan with rapamycin. Here, he and Dennis Mangan discuss how Dr. Blagosklonny's cancer research led him to the study of aging, whether rapamycin is the most important anti-aging intervention currently available, his skepticism about metformin as an anti-aging drug, and more.
Correspondence to: Mikhail V. Blagosklonny, email: Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com
Video transcript: aging-us.net/2022/06/15/inter...
Keywords: rapamycin, mTOR, aging, longevity, oncology
About Aging-US
Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer-and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.
Please visit our website at www.Aging-US.com or connect with us on:
Twitter - / agingjrnl
Facebook - / agingus
SoundCloud - / aging-us
KZfaq - / agingus
LinkedIn - / aging
Aging-US is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM